Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 7/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793814 | 0.85 | TAAR1 (0.43) | IDO1DAOTAAR1MAOB | |
| SCHEMBL626371 | 0.83 | TAAR1 (0.64) | IDO1DAOTAAR1RAD52DHODH | |
| Hydrochloric Acid SCHEMBL1970957 | 0.81 | TAAR1 (0.62) | IDO1DAOTAAR1RAD52DHODH | |
| SCHEMBL1587764 | 0.79 | IDO1 (0.50) | IDO1DAOTAAR1TACR1RAD52 | |
| SCHEMBL5776968 | 0.79 | IDO1 (0.54) | IDO1DAOTAAR1CES2TACR1 | |
| SCHEMBL6492763 | 0.78 | IDO1 (0.48) | IDO1DAOTAAR1CES2TACR1 | |
| SCHEMBL2600179 | 0.78 | IDO1 (0.48) | IDO1DAOTAAR1TACR1 | |
| SCHEMBL28842791 | 0.78 | DAO (0.49) | IDO1DAOTAAR1CES2TACR1 | |
| SCHEMBL15561899 | 0.78 | IDO1 (0.48) | IDO1DAOTAAR1CES2TACR1 | |
| SCHEMBL265044 | 0.78 | IDO1 (0.48) | IDO1DAOTAAR1CES2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006521344-A | — | — | 2006-09-21 | — | — | JP | claimed |
| US-20060122224-A1 | Quinoline and quinoxaline compounds | BECHLE BRUCE M | 2006-06-08 | — | — | US | claimed |
| WO-2006032987-A1 | INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF ARTERIOSCLEROSIS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | claimed |
| EP-1622872-A1 | 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | claimed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | claimed |
| US-20060122224-A1 | Quinoline and quinoxaline compounds | BECHLE BRUCE M | 2006-06-08 | — | — | US | disclosed |
| EP-1622872-A1 | 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122224-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | IDO1 1293/4885DAO 2279/4885TAAR1 1109/4885 |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | IDO1 1293/4885DAO 2279/4885TAAR1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.